#coinfection

Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.

Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.

Among those without cirrhosis, treating for an additional four weeks is unnecessary.

Compared with their HIV-negative peers, HIV-positive individuals have higher rates of treatment for a host of health problems.

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Aside from taking antiretrovirals, quitting smoking is the number one way people with HIV can lower their risk of illness and death.

In a recent small study of HIV-positive men who had recently contracted hepatitis C, Harvoni had a perfect cure rate.

Ending the epidemic is going to require addressing the fact that certain individuals are at high risk of reinfection after a cure.

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.

This is occurring despite the fact that hepatitis C is increasingly being cured among the French HIV population.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Consequently, researchers advocate treating hep C during its early, or acute, phase among HIV-positive individuals.

A Swiss research program tested for and treated hep C in a large cohort of HIV-positive men who have sex with men over time.

A new study identifies key changes that HIV makes to Langerhans cells in the mucosal lining of the rectum.

This is according to a recent study of a group of European men who have sex with men who were likely infected sexually.

Being coinfected with hepatitis C and having a higher HIV viral load are also associated with such a risk according to a recent study.